Cadrenal Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Cadrenal Therapeutics, Inc. (CVKD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $19.58 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-31
- Cadrenal Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $19.78, a 2004.26% increase year-over-year.
- Cadrenal Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.94.
- Cadrenal Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $19.58, a 45.25% increase from fiscal 2024.
- Cadrenal Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $13.48, a 1023.33% increase from fiscal 2023.
- Cadrenal Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.20.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 11 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $19.58 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $19.78 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | $19.78 10-Q · filed 2025-08-11 | ||||
| 2025-03-31 | $19.78 10-Q · filed 2025-05-08 | ||||
| 2024-12-31 | $13.48 10-K · filed 2025-03-13 | ||||
| 2024-09-30 | $13.48 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $0.90 10-Q · filed 2024-08-07 | ||||
| 2024-03-31 | $0.94 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | $1.20 10-K · filed 2024-03-11 | ||||
| 2023-09-30 | $1.20 10-Q · filed 2023-11-09 | ||||
| 2022-12-31 | $0.84 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |